



TARTU ÜLIKOOL



# eatris

## Fast track to clinical proof of concept

### Tailored solutions for effective collaboration

18.OCT.2017

Katrin Kaarna MD.

Clinical Research Centre

Tartu University/ Tartu University Clinics

## EATRIS PURPOSE

EATRIS is a permanent EU biomedical research infrastructure. The purpose is to **accelerate translation of science into medical products** that benefit patients and improve human health.

## EATRIS AIMS

1. Improving access to academic expertise
2. Increasing utilisation of academic infrastructure
3. Developing and validating tools that improve pipeline output
4. Facilitating public-private collaboration in research

## EATRIS SCOPE

1. Preclinical discovery to clinical proof of concept
2. Product platforms: Advanced Therapy Medicinal Products, Small Molecules, Vaccines
3. Enabling platforms: Biomarkers, Imaging & Tracing

## EATRIS BENEFITS

1. Risk-free access to evaluate European expertise
2. Multi-site and multi-disciplinary collaboration in Europe
3. Optimising translation with highly specialized expertise, as needed




**NORWAY (3)**  
 Bergen Institute of Medicine  
 Centre for Molecular Medicine Norway  
 Oslo University Hospital

**NETHERLANDS (9)**  
 University Medical Center Groningen  
 Erasmus University Medical Center  
 VU University Medical Center  
 Netherlands Cancer Institute  
 Radboud University Medical Center  
 University Medical Center Utrecht  
 Maastricht University Medical Center  
 Academic Medical Center Amsterdam  
 Leiden University Medical Center

**FRANCE (1)**  
 Albert Chevalier-Henri Mondor Hospital

**SPAIN (13)**  
 Catalan Institute of Oncology (IDIBELL)  
 Hospital Clinic of Barcelona (IDIBAPS)  
 Hospital/Institute Biodonostia  
 University Hospital La Princesa  
 Hospital de la Santa Creu i San Pau  
 Health Research Institute Santiago de Compostela  
 Hospital La Paz Institute for Health Research  
 INCLIVA Valencia  
 Institute of Biomedicine Seville  
 University Hospital Ramón y Cajal  
 Medical Research Institute of Hospital La Fe  
 Vall d'Hebron University Hospital  
 Fundación Jiménez Díaz University Hospital



**SWEDEN (3)**  
 Karolinska University Hospital  
 Lund University Hospital  
 Uppsala University Hospital

**FINLAND (3)**  
 Institute for Molecular Medicine Finland  
 Turku University Hospital  
 University of Eastern Finland Hospital

**ESTONIA (3)**  
 University of Tartu, Tartu University Clinics, Estonian University of Life Sciences

**CZECH REPUBLIC (2)**  
 Institute of Molecular and Translational Medicine Olomouc  
 Clinical Research Center of St. Anne's University Hospital Brno

**ITALY (10)**  
 National Cancer Institute, Aviano  
 IRCCS National Cancer Institute, Milan  
 Ospedale Pediatrico Bambino Gesù  
 IRCCS National Cancer Institute Giovanni Paolo II, Bari  
 IRCCS National Cancer Institute G. Pascale, Naples  
 IRCCS Luigi Maria Monti  
 Regina Elena National Cancer Institute  
 IRCCS Istituto Ortopedico Galeazzi  
 San Raffaele Scientific Institute  
 Istituto Superiore di Sanità

## OTHER RESEARCH INFRASTRUCTURES: ACCESSIBLE VIA CORBEL INNOVATION



- *biobanks*



- *data*



- *marine organisms*



- *systems biology*



- *translational research*



- *mouse disease models*



- *small molecules*



- *microorganisms*



- *clinical trials*



- *structural biology*



- *biomedical imaging*

## EXAMPLES OF CURRENT PROJECTS

1. 5-site immune-inflammation imaging hub for UK-based large pharma
2. 3-site  $^{89}\text{Zr}$  antibody imaging hub for medium European biopharma
3. Single-site primate  $^{89}\text{Zr}$  antibody imaging for international Japanese pharma
4. Collaboration with Kyushu University: best practice, staff exchange in joint research
5. **Pre-clinical toxicology – GLP license ( Estonia )**

## EXAMPLES OF PROJECTS IN DEVELOPMENT


1. EANM EARL accreditation for  $^{89}\text{Zr}$  PET-CT imaging, with 10-14 sites in pilot
2. Exploring concept for trial-ready network in tau imaging
3. Imaging of Progressive Supranuclear Palsy and epilepsy patients with a novel tracer
4. **Biomarkers for osteosarcoma for personalized management ( Estonia)**





# Failing too late in development

Ca 65% fail at phase II







TARTU ÜLIKOOL



## Translational Research Perspective

- From deep, intra-disciplinary exploration to multi-disciplinary, **validatory** research
- Many factors beyond the scientific concept are **needed to success**:
  - ✓ Creating a **product that is viable**
  - ✓ Creating and testing a product that fits to the **development** workflow (**stage-gating**)
  - ✓ Convincing **industry** that the products represents value
  - ✓ Convincing the **regulators** that the product is safe and effective
  - ✓ Convincing the **government officials** that the product is cost-effective
  - ✓ Convincing the **doctors** that the product addresses the medical needs



# Clinical Research Centre

